Aragon-Ching Jeanny B
GU Medical Oncology, Inova Schar Cancer Institute, Department of Medicine, Virginia Commonwealth University, Fairfax, VA.
Urol Oncol. 2017 Jul;35(7):462-464. doi: 10.1016/j.urolonc.2017.05.023.
Urothelial carcinomas span the bladder, ureter, and renal pelvis, and while there had been stagnation in the field of drug approval for the past two decades, there is now accelerated and regular US FDA approval of 5 immunotherapy agents. However, patients who inherently do not respond or progress on such therapies still represent an area of increased unmet need. In this special Seminars issue, we explore varying aspects of bladder urothelial carcinoma treatment with targeted therapies, the unique presentation and challenges in the treatment of upper tract and renal pelvis tumors, as well as new and emerging diagnostic imaging tools for varying genitourinary cancers.
尿路上皮癌累及膀胱、输尿管和肾盂，在过去二十年里，药物批准领域一直停滞不前，但现在美国食品药品监督管理局（FDA）加速并定期批准了5种免疫治疗药物。然而，那些对此类疗法天生无反应或病情进展的患者，仍然是未满足需求增加的领域。在本期特刊《研讨会》中，我们探讨了膀胱尿路上皮癌靶向治疗的各个方面、上尿路和肾盂肿瘤治疗中的独特表现及挑战，以及针对各种泌尿生殖系统癌症的新兴诊断成像工具。
